Breaking News Instant updates and real-time market news.

TXMD

TherapeuticsMD

$5.67

0.5 (9.67%)

08:21
04/12/18
04/12
08:21
04/12/18
08:21

TherapeuticsMD talks with FDA incrementally positive, says Jefferies

Jefferies analyst Matthew Andrews believes label negotiations with the FDA on TX-004 is incrementally positive for TherapeuticsMD. The company is one step closer to approval after a tough 2017, Andrews tells investors in a research note. Amid the potential for two FDA approvals in 2018, no near-term financing overhang and potential for stronger than expected TX-004 launch, shares of TherapeuticsMD are undervalued, the analyst contends. He keeps a Buy rating on the stock with a $15 price target.

  • 08

    May

  • 29

    May

  • 28

    Oct

TXMD TherapeuticsMD
$5.67

0.5 (9.67%)

01/16/18
JEFF
01/16/18
NO CHANGE
Target $15
JEFF
Buy
TherapeuticsMD undervalued at current share levels, says Jefferies
Following a dinner with management, Jefferies analyst Matthew Andrews calls shares of TherapeuticsMD undervalued. TX-004HR is a differentiated novel estrogen drug while TX-001HR is a potential new "gold standard" in vasomotor symptoms, Andrews tells investors in a research note partially titled "2018 to Bring Innovation Back to Women's Health." With new drug applications for both under FDA review, TherapeuticsMD is on track for two approvals in 2018, a "rare biopharma achievement," in the multi-billion vaginal atrophy and vasomotor symptoms markets, the analyst writes. He keeps a Buy rating on TherapeuticsMD with a $15 price target.
02/21/18
JEFF
02/21/18
NO CHANGE
Target $15
JEFF
Buy
TherapeuticsMD undervalued into 'transformative' 2018, says Jefferies
Jefferies analyst Matthew Andrews believes 2018 is set up to be a "transformative" year for TherapeuticsMD with two FDA approvals, which he notes is a rarity in small-cap biotech. Finalization of a $200M term loan prior to TX-004HR approval will remove any financing overhang and helps fund both drugs' launches, Andrews tells investors in a research note. He views the stock as undervalued and thinks TX-001HR can become the vasomotor symptoms "gold-standard drug" with $2B-plus in sales. The analyst keeps a Buy rating on TherapeuticsMD with a $15 price target.
02/21/18
CANT
02/21/18
NO CHANGE
Target $28
CANT
Overweight
TherapeuticsMD could have 'breakout year' in 2018, says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner reiterates an Overweight rating and $28 price target on shares of TherapeuticsMD following the company's Q4 results. The possibility of dual approvals could make for a "breakout year" in 2018, Tanner tells investors in a post-earnings research note. He believes TX-004 could become an important therapy with which to treat vulvar vaginal atrophy. Further, the "evolving regulatory landscape" for drug compounders should position TX-001 as an attractive alternative commercial product for compounding pharmacies, the analyst adds.
04/12/18
CANT
04/12/18
NO CHANGE
Target $28
CANT
Overweight
TherapeuticsMD talks with FDA 'tacit sign' of approval, says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner views TherapeuticsMD's disclosure of label negotiations with the FDA regarding TX-004 as a "tacit sign that the drug will be approved." The FDA action date is May 29 "so such an activity would be expected were the Agency prepared to issue a positive decision, in our experience," Tanner told investors yesterday in a research note. He cautions investors from viewing as probable an approval with a label that does not contain the estrogen class black box warning. However, given the drug's "tortuous development path," he believes any approval is a "clear positive." The analyst has an Overweight rating on TherapeuticsMD with a $28 price target.

TODAY'S FREE FLY STORIES

BHVN

Biohaven Pharmaceutical

$27.19

-0.07 (-0.26%)

05:21
04/23/18
04/23
05:21
04/23/18
05:21
Hot Stocks
Biohaven announces key secondary outcome measures from rimegepant Phase 3 trials »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 12

    Jun

OPBK

OP Bancorp

05:12
04/23/18
04/23
05:12
04/23/18
05:12
Initiation
OP Bancorp initiated  »

OP Bancorp initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$58.82

0.18 (0.31%)

05:11
04/23/18
04/23
05:11
04/23/18
05:11
Upgrade
Merck rating change  »

Merck upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 27

    Apr

  • 01

    May

  • 08

    May

  • 05

    Jun

  • 23

    Oct

BDORY

Banco do Brasil

05:04
04/23/18
04/23
05:04
04/23/18
05:04
Downgrade
Banco do Brasil rating change  »

Banco do Brasil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STT

State Street

$99.64

-4.57 (-4.39%)

05:02
04/23/18
04/23
05:02
04/23/18
05:02
Upgrade
State Street rating change  »

State Street upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

KORS

Michael Kors

$65.02

-0.7 (-1.07%)

04:57
04/23/18
04/23
04:57
04/23/18
04:57
Upgrade
Michael Kors rating change  »

Deutsche Bank upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$12.60

-0.47 (-3.60%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Syros Pharmaceuticals management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    May

AVEO

Aveo Oncology

$2.59

-0.05 (-1.89%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Aveo Oncology management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

CIGI

Colliers International

$70.20

0.75 (1.08%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
UBS REITs analyst to hold an analyst/industry conference call »

REITs Analyst Yulico,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 30

    Apr

  • 01

    May

CNAT

Conatus

$3.58

0.02 (0.56%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Conatus management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

KMB

Kimberly-Clark

$100.04

-3.3 (-3.19%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Technical Analysis
Technical Earnings Preview: Kimberly-Clark near 5-year lows ahead of earnings »

The shares of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 27

    Apr

  • 30

    May

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Existing Home Sales to be reported at 10:00 »

March Existing Home Sales…

INFY

Infosys

$17.38

0.21 (1.22%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Infosys to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

MLNX

Mellanox

$75.80

-1.45 (-1.88%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Mellanox management to meet with Loop Capital »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

APVO

Aptevo Therapeutics

$4.33

0.01 (0.23%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Aptevo Therapeutics management to meet with Piper Jaffray »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

April PMI Composite Flash…

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

IFRX

InflaRx

$38.78

1.67 (4.50%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
InflaRx has a conference call hosted by JPMorgan »

JPMorgan Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Leerink healthcare analysts to hold an analyst/industry conference call »

Analysts discuss dental…

LUK

Leucadia

$24.02

-0.1 (-0.41%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Leucadia management to meet with Oppenheimer »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    May

  • 04

    Oct

CNK

Cinemark

$39.66

-0.74 (-1.83%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Cinemark management to meet with MKM Partners »

Meeting to be held in Las…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

CRAY

Cray

$22.40

-0.2 (-0.88%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Cray management to meet with Craig Hallum »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 29

    May

SNX

Synnex

$103.51

-0.33 (-0.32%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Synnex management to meet with Loop Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 03

    May

  • 04

    May

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

March Chicago Fed…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.